Ensign Peak Advisors
CSTL icon

Ensign Peak Advisors’s Castle Biosciences CSTL Stock Holding History

Ensign Peak Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,090
Closed -$81K – 1886
2022
Q3 		$81K Buy
3,090
+2,200
+247% +$61.7K ﹤0.01% 2137
2022
Q2 		$20K Hold
890
– – ﹤0.01% 2125
2022
Q1 		$40K Hold
890
– – ﹤0.01% 2148
2021
Q4 		$38K Buy
+890
New +$46.5K ﹤0.01% 2157
2021
Q1 		– Sell
-12,505
Closed -$840K – 1838
2020
Q4 		$840K Sell
12,505
-14,970
-54% -$811K ﹤0.01% 1466
2020
Q3 		$1.41M Buy
27,475
+18,109
+193% +$806K ﹤0.01% 1154
2020
Q2 		$353K Buy
9,366
+5,354
+133% +$183K ﹤0.01% 1520
2020
Q1 		$120K Sell
4,012
-16,339
-80% -$493K ﹤0.01% 1567
2019
Q4 		$699K Buy
+20,351
New +$498K ﹤0.01% 1455

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ensign Peak Advisors's CSTL Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Castle Biosciences (CSTL) in Q4 2022, closing a stake of 3,090 shares — an estimated $81K sold.

Ensign Peak Advisors first reported a position in CSTL in Q4 2019 and held it in 9 quarters. The position peaked at $1.41M in Q3 2020. 153 funds tracked by Wall St. Rank hold CSTL as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Castle Biosciences position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 3,090 Castle Biosciences shares in Q4 2022, an estimated $81K.
  • Ensign Peak Advisors first reported a position in Castle Biosciences in Q4 2019 and held it in 9 quarters.
  • Ensign Peak Advisors's Castle Biosciences position peaked at $1.41M in Q3 2020.
  • 153 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.